Ximena Lopez
Pediatric Endocrinology · San Diego, CANPI 1740316405
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.8% of the total across 87 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 22 manufacturers, the largest accounting for just 17.0% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $834, more than ten times the $13 reported in 2019.
Across 87 payments — averaging $24.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$363
- Dexcom, Inc.$267
- AbbVie$184
- Eton Pharmaceuticals, Inc.$164
- Azurity Pharmaceuticals, Inc.$149
- Tolmar, Inc.$119
- plus $894 from 16 others
Across 8 payments — averaging $3623.72 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novo Nordisk AS$23K
- Daiichi Sankyo Inc.$6K
What the payments were for
- Food & beverage$2,09398%
- Education$482%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 16 | $363 |
| Dexcom, Inc. | 11 | $267 |
| AbbVie | 8 | $184 |
| Eton Pharmaceuticals, Inc. | 3 | $164 |
| Azurity Pharmaceuticals, Inc. | 8 | $149 |
| Tolmar, Inc. | 4 | $119 |
| Merz Pharmaceuticals, LLC | 5 | $106 |
| Tandem Diabetes Care, Inc. | 4 | $104 |
| Genentech USA, Inc. | 5 | $103 |
| Neurocrine Biosciences, Inc. | 4 | $100 |
| Insulet Corporation | 3 | $82 |
| Biomarin Pharmaceutical Inc. | 1 | $79 |
| Kyowa Kirin, Inc. | 3 | $76 |
| Ascendis Pharma Endocrinology Inc | 2 | $58 |
| Pfizer | 2 | $42 |
| Lilly USA, LLC | 2 | $33 |
| BETA Bionics, Inc. | 1 | $25 |
| Sequel Med Tech, LLC | 1 | $23 |
| Sanofi-aventis U.S. LLC | 1 | $19 |
| Abbott | 1 | $17 |
| Soleno Therapeutics, Inc. | 1 | $15 |
| Tolmar Pharmaceuticals, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,141 in reported general payments places this provider in the 60th percentile of 168 pediatric endocrinology providers in California.
Other pediatric endocrinology in San Diego
- Karen KleinSan Diego$195K
- Marcela Vargas TrujilloSan Diego$57K
- Ron NewfieldSan Diego$27K
- Michael GottschalkSan Diego$17K
- Susan PhillipsSan Diego$12K
- Maja MarinkovicSan Diego$5K
- Mary PattersonSan Diego$4K
- Jane KimSan Diego$3K
- Gnanagurdasan PrakasamSacramento$805K
- Swati ElchuriVentura$210K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.